Key Abstracts Yield Insights Into Combinations and Dosing in Myeloproliferative Neoplasms

Published: Thursday, Apr 04, 2013
Dr. Srdan Verstovsek
Srdan Verstovsek, MD, PhD

Professor Department of Leukemia
The University of Texas MD Anderson Cancer Center, Houston, TX

Dr. Ruben A. Mesa
Ruben A. Mesa, MD

Chair, Hematology Department of Hematology/Oncology
Mayo Medical School, Mayo Clinic Rochester, MN

Combining two commonly used drugs for myeloproliferative neoplasms achieved what the individual drugs could not: a high response rate with few side effects, as reported at the Eighth Annual Hematologic Malignancies 2012 Conference, held in Houston in October 2012.

A low-dose combination of hydroxyurea and anagrelide led to complete remission in 8 of 12 patients with polycythemia vera or essential thrombocythemia. Three other patients had partial responses. All 12 patients had Philadelphia chromosome-negative disease that had proven resistant or refractory to monotherapy. Patients have maintained remission during a mean treatment duration of 51 months.

“This is the largest number of patients and longest follow-up of hydroxyurea and anagrelide in myeloproliferative neoplasms refractory or intolerant to monotherapy,” concluded Inhye E. Ahn, MD, a hematologist at The University of Texas MD Anderson Cancer Center in Houston, and colleagues in a poster presentation.

“Rather than substitute for an agent that has had partial success or is causing dose-related side effects, adjusting the dose and adding a second agent offers highly effective therapy. In fact, future studies might explore combination therapy as initial therapy, to limit side effects and optimize response rates.”

The study was one of several that provided new and updated information about ongoing research to improve outcomes in myeloproliferative disorders.

Dose-dependent cytopenias did not reflect worsening disease status in patients with myelofibrosis treated with the JAK-2 inhibitor ruxolitinib in a large randomized clinical trial. Cytopenias tended to occur early in the course of treatment in the COMFORT- I trial and generally were manageable with dose adjustments and treatment interruptions, reported Srdan Verstovsek, MD, PhD, and colleagues.

Because thrombopoietin and erythropoietin signal exclusively through the JAK2 pathway, JAK2 inhibition would be expected to cause thrombocytopenia and anemia. COMFORT-I was a placebocontrolled trial that evaluated ruxolitinib in patients with myelofibrosis. Ruxolitinib therapy started at a dose of 15 mg twice daily for patients with platelet counts of 100 to 200 x 109/L, and 20 mg twice daily for patients with higher platelet counts.

Although adverse events were monitored in the trial, the time course of cytopenias and management with dose reductions (and transfusions, in the case of anemia) had not been thoroughly examined. Analysis of the data showed that 87 of 155 patients treated with ruxolitinib required one or more dose reductions, and 49 of the 87 patients required a single dose reduction.

Dose adjustments typically occurred during the first eight to 12 weeks of treatment, and platelet counts remained stable thereafter, said Verstovsek, a professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. Dose reductions occurred most often in patients who had baseline platelet counts of 100 to 200 x 109/L.

The need for red blood cell transfusion also peaked during the first eight to 12 weeks of treatment with ruxolitinib, and then returned to baseline levels.

Another analysis of COMFORT-I examined the relationship between the final titrated dose of ruxolitinib and efficacy. The trial had a primary endpoint of at least a 35% reduction in spleen volume at week 24, as measured by abdominal MRI or CT. The principal secondary endpoint was at least a 50% reduction in total symptom score (TSS) on the modified Myelofibrosis Symptom Assessment Form.

Among patients who began treatment at 15 mg twice daily, the median final titrated dose was 10 mg twice daily, reported Ruben A. Mesa, MD, director of the Acute and Chronic Leukemias Program at the Mayo Clinic in Scottsdale, Arizona. The median for patients who began treatment at the higher dose was 20 mg twice daily.

The results showed that patients who had a final titrated dose ≤5 mg twice daily had only a 10% reduction in spleen volume. In contrast, the decline averaged 31% in patients who had a final titrated dose of 10 mg twice daily. Higher doses resulted in more modest improvement: 36% for 15 mg twice daily, 38% for 20 mg twice daily, and 41% for 25 mg twice daily.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication